A large Swedish registry study suggests that GLP-1 receptor agonists — notably semaglutide (marketed as Ozempic and Wegovy) and liraglutide — are associated with a lower risk of…
Stopping GLP-1 medications such as semaglutide (Ozempic, Wegovy) can rapidly erase the cardiovascular gains achieved while using them.
A recent analysis suggests the high-dose semaglutide product Wegovy may be associated with an elevated reporting rate of ischemic optic neuropathy (ION), a rare but serious cause of…
GLP-1 medications such as Ozempic and Wegovy typically produce about 15–20% body-weight loss, and are often prescribed as long-term therapies because many people regain weight after…
A study published March 3 in Cell Metabolism reports that semaglutide — the active ingredient in GLP‑1 drugs such as Ozempic and Wegovy — may help repair cartilage in osteoarthritis by…
A recent observational study published March 3 in BMJ Open Diabetes Research & Care found that sleeping about 7 hours and 19 minutes per night was associated with the lowest estimated…
A large observational analysis published in The Lancet Diabetes & Endocrinology examined more than 98,000 adults with type 2 diabetes and no prior cardiovascular disease.
A recent analysis found that higher red meat consumption was linked with greater odds of type 2 diabetes, while replacing red meat with other protein sources—especially plant…
Reports of people taking GLP-1 medications being diagnosed with scurvy have risen. The drugs don’t directly deplete vitamin C; rather, their common effects—reduced appetite and slower…
New research suggests tirzepatide—the active drug in Mounjaro and Zepbound—may be linked to a lower short-term risk of diabetic retinopathy in people with type 2 diabetes.
A large pooled analysis published in the Journal of Sport and Health Science found that low levels of physical activity are associated with many complications of type 2 diabetes…
A recent observational study found that about 7 hours 18 minutes of sleep per night was associated with the lowest risk of insulin resistance, a key precursor to type 2 diabetes.